0001213900-23-033285.txt : 20230427 0001213900-23-033285.hdr.sgml : 20230427 20230427162633 ACCESSION NUMBER: 0001213900-23-033285 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230426 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230427 DATE AS OF CHANGE: 20230427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avalon GloboCare Corp. CENTRAL INDEX KEY: 0001630212 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471685128 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38728 FILM NUMBER: 23857433 BUSINESS ADDRESS: STREET 1: 4400 ROUTE 9 STREET 2: SUITE 3100 CITY: FREEHOLD STATE: NJ ZIP: 07728 BUSINESS PHONE: 732-780-4400 MAIL ADDRESS: STREET 1: 4400 ROUTE 9 STREET 2: SUITE 3100 CITY: FREEHOLD STATE: NJ ZIP: 07728 FORMER COMPANY: FORMER CONFORMED NAME: Avalon Globocare Corp. DATE OF NAME CHANGE: 20161018 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL TECHNOLOGIES CORP DATE OF NAME CHANGE: 20150108 8-K 1 ea177537-8k_avalon.htm CURRENT REPORT
0001630212 false 0001630212 2023-04-26 2023-04-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 26, 2023

 

AVALON GLOBOCARE CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38728   47-1685128

(State or other jurisdiction

of incorporation)

  

(Commission File Number)

  

(IRS Employer

Identification No.)

 

4400 Route 9 South, Suite 3100

Freehold, NJ 07728

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (732) 780-4400

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbols   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALBT   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Explanatory Note.

 

Unless otherwise stated or unless the context otherwise requires, the terms “we,” “us,” “our,” “Avalon,” and the “Company” refer to Avalon GloboCare Corp., a Delaware corporation.

 

On February 9, 2023 (the “Closing Date”), the Company entered into and closed an Amended and Restated Membership Interest Purchase Agreement (the “Amended MIPA”), by and among Avalon Laboratory Services, Inc., a wholly-owned subsidiary of the Company (the “Buyer”), SCBC Holdings LLC (the “Seller”), the Zoe Family Trust, Bryan Cox and Sarah Cox as individuals (each an “Owner” and collectively, the “Owners”), and Laboratory Services MSO, LLC (“Laboratory Services MSO”). Pursuant to the terms and conditions set forth in the Amended MIPA, Buyer acquired, on the Closing Date, forty percent (40%) of all the issued and outstanding equity interests of Laboratory Services MSO (the “Purchased Interests”) from the Seller, free and clear of all liens (the “Transaction”). The Amended MIPA was filed as Exhibit 2.1 to the Current Report on Form 8-K with the Securities Exchange Commission (the “SEC”) on February 13, 2023 (the “Form 8-K”).

 

On April 26, 2023, in connection with the Transaction, the Company filed an amendment to the Form 8-K in order to include: (i) the audited consolidated financial statements of Laboratory Services MSO for the fiscal years ended December 31, 2022 and 2021, respectively, and the related notes thereto; and (ii) the unaudited pro forma condensed combined financial information of the Company and Laboratory Services MSO, as of and for the fiscal year ended December 31, 2022 (the “Form 8-K/A”).

 

Item 2.02. Results of Operations and Financial Condition.

 

On April 27, 2023, the Company issued a press release regarding the audited consolidated financial statements of Laboratory Services MSO for the fiscal years ended December 31, 2022 and 2021, respectively, and the related notes thereto, as set forth in the 8-K/A. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

The information contained in this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Cautionary Note Regarding Forward-Looking Statements.

 

This report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties that exist in the Company’s operations and business environment, which may be beyond the Company’s control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements regarding prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company. Forward-looking statements represent the judgment of management of the Company regarding future events. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable at the time that they are made, the Company can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Company assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

 

1

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is furnished herewith:

 

Exhibit No.   Exhibit
     
99.1*   Press Release issued by the Company, dated April 27, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

*Filed herewith.

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AVALON GLOBOCARE CORP.
   
Date: April 27, 2023 By: /s/ Luisa Ingargiola
  Name:  Luisa Ingargiola
  Title: Chief Financial Officer
 

 

3

 

 EX-99.1 2 ea177537ex99-1_avalon.htm PRESS RELEASE ISSUED BY THE COMPANY, DATED APRIL 27, 2023

Exhibit 99.1

 

 

Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022

 

40% Profit Sharing Arrangement with Laboratory Services MSO is Expected to Result in Significant Future Cash Flow to the Company

 

FREEHOLD, N.J., April 27, 2023 (GLOBE NEWSWIRE) – Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today reported financial results for Laboratory Services MSO, LLC (“LSM”) for the twelve months ended December 31, 2022. In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and reference laboratory.

 

LSM 2022 Financial Highlights

 

·Revenue was $14.7 million
·Gross profit was $8.1 million
·Total operating expense was $2.4 million
·Net income was $6.3 million

 

“We are pleased to report strong financial results and profitability for LSM in 2022, which we believe is further validation of our strategic investment,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “LSM offers an extensive test menu, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, with quick turnaround times. Our goal is to continue to grow LSM’s top and bottom line by taking advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with exceptional performance, a positive revenue track record and niche-market advantage, we believe we can effectively leverage LSM’s experience and infrastructure to achieve significant synergies.”

 

Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.

 

About Avalon GloboCare Corp.

 

Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

 

 

 

 

For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco

 

Forward-Looking Statements

 

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding LSM. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

 

Contact Information:

 

Avalon GloboCare Corp.

4400 Route 9, Suite 3100

Freehold, NJ 07728

PR@Avalon-GloboCare.com

 

Investor Relations:

 

Crescendo Communications, LLC

Tel: (212) 671-1020 Ext. 304

albt@crescendo-ir.com

 

(tables follow)

 

2

 

 

LABORATORY SERVICES MSO, LLC AND AFFILIATES

COMBINED BALANCE SHEETS

 

   December 31, 
   2022   2021 
ASSETS        
         
CURRENT ASSETS:        
Cash  $439,778   $607,982 
Accounts receivable   4,088,069    3,086,966 
Other current assets   86,277    - 
           
Total Current Assets   4,614,124    3,694,948 
           
NON-CURRENT ASSETS:          
Operating lease right-of-use assets, net   1,758,063    - 
Finance lease right-of-use assets, net   291,419    - 
Property and equipment, net   14,667    18,667 
           
Total Non-current Assets   2,064,149    18,667 
           
Total Assets  $6,678,273   $3,713,615 
           
LIABILITIES AND MEMBER’S EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable  $573,395   $184,139 
Accrued payroll liability   38,589    42,077 
Operating lease obligation   229,874    - 
Finance lease obligation   112,457    - 
           
Total Current Liabilities   954,315    226,216 
           
NON-CURRENT LIABILITIES:          
Operating lease obligation - noncurrent portion   1,680,017    - 
Finance lease obligation - noncurrent portion   178,962    - 
           
Total Non-current Liabilities   1,858,979    - 
           
Total Liabilities   2,813,294    226,216 
           
Commitments and Contingencies (Note 8)          
           
MEMBER’S EQUITY   3,864,979    3,487,399 
           
Total Liabilities and Member’s Equity  $6,678,273   $3,713,615 

 

See accompanying notes to the combined financial statements.

 

3

 

 

LABORATORY SERVICES MSO, LLC AND AFFILIATES

COMBINED STATEMENTS OF INCOME

 

   For the Year Ended   For the Year Ended 
   December 31,
2022		   December 31,
2021		 
         
         
REVENUE  $14,689,747   $18,278,430 
           
COST OF REVENUE   6,612,268    5,002,674 
           
GROSS PROFIT   8,077,479    13,275,756 
           
OPERATING EXPENSES:          
Selling and marketing expense   1,344,552    480,269 
Professional fees   714,662    375,667 
Other general and administrative expenses   296,704    281,128 
           
Total Operating Expenses   2,355,918    1,137,064 
           
OPERATING INCOME   5,721,561    12,138,692 
           
OTHER INCOME (EXPENSE)          
Forgiveness of Paycheck Protection Program loan   -    95,000 
Employee Retention Tax Credit   609,634    - 
Other income   11,938    24,330 
           
Total Other Income, net   621,572    119,330 
           
INCOME BEFORE INCOME TAXES   6,343,133    12,258,022 
           
INCOME TAXES   -    - 
           
NET INCOME  $6,343,133   $12,258,022 

 

See accompanying notes to the combined financial statements.

 

 

4

 

 

 EX-101.SCH 3 albt-20230426.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 albt-20230426_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 albt-20230426_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HJ M-KB%)1$TT:R-T4L 3^%24"NBK)J5E%>):2742W#_ '8RWS&K5>?:SX>FF\;0 M;9/DNV\W=W3;U'^%>@@8 %:SA&*33W.3#5ZE64U.-N5V7F%%,::)9!&TB"1N MBEAD_A3ZR.RX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110!X;XKL=8M_$EY<7,=P6\PO'.H) 7^'!'3%>M^&-576/#] MI=APTA0+)@]&'!S6LRJZE64,#V(S7E/C1KKPOXD6XTB=[2.[CWLD?W2P//'3 MTKN4OK"5.UFCPW2_L^4J]W*+W77U-+6=9OD\ST/X=ZY>SUW7/%NKVVEW-ZZV M\[_O4A&T;.IINA*>^BCN9TL7&@V[N3J.Z5K6Z:_UT,B[N-1UOQ%-.G05[O:"9;*!;@YF$:B0^K8Y_6F6=A::? L-I;QPHHP BXJS6->L MJEDE9([\#@GAW*4I7]ET_P .64S17&H29D=#@I&O M4U8\"ZA--I3^S]/NUMQ$"=K1]&;'XTTA M-V/6**9#,EQ!'-&VZ.10RGU!I](845Q?@V663Q+XI5Y'95O<*&8D 8[>E=I0 M 4QYHHB!)(B9Z;F S7/>+]=N=*M+>TTU ^IW\GDVX/1?5C]*S[;X7E_>OS)(TQ4 ^P'2F*YV@((R.117GUQ;WOP^OK>X@NY[K09Y!'-%.VYH">C M ^E>@*P90RG((R#0 M%>;^+[K5[?Q]9/I#,\T5FTI@W?+(H.6&/7%=MH>M6N MOZ7%?6K<-PZ'K&W=3[T6"YI45Q?AJ:5_'_B='E=D4Q;5+$@<=A7:4AB/DHP7 MAL)PD:\HR=".BVF1@^XZT_7[O3+'P[I]OXGMVN[TKE43[X]3N[=JZ^\U7 M3]/'^EWD,/L[@&O.=:TZ^\>ZV;K3% TZ!?*2XEX#'N0.]=-)\UN;1+KL>;B: M2HN3I-SG+2SU^=O\SJM(U+PX?"$L]O$D6FQJ1-$R\@]P1W)K(\(7WAB?4+B' M2+-[6^=&\MI>'M)TS09_#=WJ$Q7D5LV]UB.&*]^#[5<8TVI+F>NWF3.I7BZ(]*\4W,B%Y?M,8^ZMM\H4^X_K75Z7XCTG6$4V=Y M&SL,^63AA[$5JU@ZTU*[BK^AT0RZC.BX0J2:?F4])BN8=*MH[Q]UPJ 2'.>: MN$@ DG %%5=1M7O=-N;6*8PO+&4$@&2N1C-<[=W<]:,>6*BNAYWIVMW%SXPU M/78M'OM0A7_1K9K=0511UZ]S3[?6);'XA0WTVEW>G6VJ(()!<* &D'0BNYT' M1X=!T:WTZ!BRQ#ER.68]2:@\2^'X_$6F"U:4PRQR++%*HR48&G<+&S7*^/=- MENM"6_M5_P!,TZ07,1'4@=1^7\JZ>)62%$=R[*H!8]SZTKHLD;(XRK @@]P: MDH\_O-0C\9ZWH5A P>S6,7UUCU'13^->A 8&!7.>%_"-KX8>]>&4RO1 M++!*,,IKDH_"'B#3 8-&\3O%9_P17,0D*#T!H D^(]U&?#HTI,/>7\J10QCK MG(.?I76VL9AM(8F.62-5/X"N=T3P='8:A_:FI7DNI:GC FFZ1C_9':NGH!'$ MWO\ R5W3/^O&2FZQ:3^$=9;Q#IL3/ITY U&U3^'_ *:J/7UK>G\/K-XMMM=^ MT,#! T/E8X.>^:V'19$9'4,K#!!Z$47"QPO@ZYAO/''B2YMY%DAE6)D=>A!% M=Y7.>'?"%MX;U34+FTE8PW>W;"1Q'C)P#^-='0P04444AGB.O^'=NEZ/:V2@?N8PIQZ]_P!:O45T5:\JD5%]#@PN M!AAYRFG=R.!U_P ./<>,+8H_[N];A&*\[\0ZEJ2^-(-D M;YMW @0#[X/4_C7HHR0,]:*W-RQOV,,![-U:W(K>]_7XW/"[[PWJ]IXB>VM[ M*?S/.S"Z*<8SP0>U>X6RR):PK,VZ4(H<^K8YJ6BBM7=5)-;&^$P,<*Y.+;N% M%%%NG3]*VZ*0'.W=U=KJ$BB6=9PZ?9X0GR.O&QKI**86,311J"!9KZ5@DJ*%1FW$OR<]!CZ5MT44AA1110 4444 M-*(6#%5+#H2.13J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3 **** "BBB@ HHHH **** /_V0$! end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 26, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 26, 2023
Entity File Number 001-38728
Entity Registrant Name AVALON GLOBOCARE CORP.
Entity Central Index Key 0001630212
Entity Tax Identification Number 47-1685128
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4400 Route 9 South
Entity Address, Address Line Two Suite 3100
Entity Address, City or Town Freehold
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07728
City Area Code 732
Local Phone Number 780-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ALBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 ea177537-8k_avalon_htm.xml IDEA: XBRL DOCUMENT 0001630212 2023-04-26 2023-04-26 iso4217:USD shares iso4217:USD shares 0001630212 false 8-K 2023-04-26 AVALON GLOBOCARE CORP. DE 001-38728 47-1685128 4400 Route 9 South Suite 3100 Freehold NJ 07728 732 780-4400 false false false false Common Stock, par value $0.0001 per share ALBT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %"#FU8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !0@YM6#'&O<^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*'%&"R;U9:6G#08K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/ MGT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2.27ZJ7GPT2F:GO$(0>D/ M=43@5;4"AZ2,(@4SL @+D^"V@68J[^BWI\26O6]@^ MD>HU3K^2%70.N&'7R:_-PW:_8Y)7O"FJ^X*O][P2?"7X^GUV_>%W$W;>V(/] MQ\970=G"K[N07U!+ P04 " !0@YM6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M %"#FU8 KCO(9 0 "01 8 >&PO=V]R:W-H965T&UL MC9C1E,<18604G<\ERWVTJ82)W1H+@V4Z.!S$TL4CY31.=)PM3; M+8_E=NA0Y_W"7&PB8R^T1H.,;?B"FS^SF8)6JU0)1<)3+61*%%\/'9_>W'I7 M-J!XXJO@6WUP3FQ75E(^V\9#.'1<2\1C'A@KP>#PPL<\CJT2<'S?BSKE.VW@ MX?F[^GW1>>C,BFD^EO$W$9IHZ/0=$O(URV,SE]O?^+Y#!6 @8UW\)]O=LYV. M0X)<&YGL@X$@$>GNR%[WB3@,Z!X)\/8!7L&]>U%!><<,&PV4W!)EGP8U>U)T MM8@&.)':45D8!7<%Q)G16+YP-6@9D+(76L$^['87YAT)\S-U2;SN.?%B>$5>FT,@_SMK[11,%#_U!'M%#KU"K9Z;W3& CYTH#PU5R_<&?WT M ^VZOR)\[9*OC:F/[F200RT:LGS+>!T<'MZ_^(Q =$J(#JKB T%84-S';%-' M@<>O6:PYPG%5M/L]KX_P]$J>WBD\<[X1MK(A9T\LJ4T4KN-_]1^G3V>? M'J>WT[$_GY#Q=#Z[1 #[)6#_%, Q#*=B,7E(0_Y*/O.W.D1R4,(;&(M E;8^/%1Q14[O0O:[5]1=%BI6]FF>PK@0QI(E4E5 ML)V3A8%I0*0B8YE#0B&O,JP=[0;UNPD&>>#M]!1(/PS!$?7Y^PEYA.?(-*TG MPR4['=<]F\/RSLDU6< QPD@K^Z>H>^.DRZVL)<4E%[D R#9U78RP6@ H;N$? M"<>V!2.]E-NTE@Z7NU><1S(.,;9J7:"XL7]D*\MPIN2+2(/Z@<8UGW['T*JE M@N(._Q%M)K4!G_E+9,?G!J[H]G!KIM5:07&C+X;0A[WL<11M0)XN$?/%+\((#T"@/[,[DFU/MY M]0M9\""'>JO=*A;:&ER\)2M96X$- O[C[1(CJ5S?PQWZ/6UD\AI$+-WPHWO+!J$G M?W'G_X$Q57;OG63WDX2KCQ MS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G M55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4 M)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(R MA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[ M##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R M 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0< MO(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q M]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9 MQP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR M'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH< M8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ 4(.;5I>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX M1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\ MG7D(GP&LK\,S4-AB. MG8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H M YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;* MO8=7LN48Y0]02P,$% @ 4(.;5B0>FZ*M ^ $ !H !X;"]? M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2* M+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\ M7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7 M-_=%KLWC":[?#'!X=/X!4$L#!!0 ( %"#FU9ED'F2&0$ ,\# 3 M6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/ M&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB M>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9 M/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1 MB5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9 M_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 M Q0 ( %"#FU8 KCO(9 0 "01 8 " @0T( !X;"]W M;W)K&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " !0@YM699!YDAD! #/ P $P @ &Q$@ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #[$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avalon-globocare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea177537-8k_avalon.htm albt-20230426.xsd albt-20230426_lab.xml albt-20230426_pre.xml ea177537ex99-1_avalon.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea177537-8k_avalon.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea177537-8k_avalon.htm" ] }, "labelLink": { "local": [ "albt-20230426_lab.xml" ] }, "presentationLink": { "local": [ "albt-20230426_pre.xml" ] }, "schema": { "local": [ "albt-20230426.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ALBT", "nsuri": "http://avalon-globocare.com/20230426", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea177537-8k_avalon.htm", "contextRef": "From2023-04-26to2023-04-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://avalon-globocare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea177537-8k_avalon.htm", "contextRef": "From2023-04-26to2023-04-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001213900-23-033285-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-033285-xbrl.zip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